5-Amino-3-(trifluoromethyl)pyridine-2-carbonitrile, molecular formula C₇H₄F₃N₃ and molecular mass 187.12 g/mol, is supplied as a pharmaceutical-grade active pharmaceutical ingredient for formulation into oral tablet, capsule, granule, and injectable dosage forms. The compound is a trifluoromethyl-substituted aminopyridine carbonitrile in which the nitrile is located at the 2-position, trifluoromethyl at the 3-position, and amino at the 5-position. This regiochemistry produces a crystalline powder with halogenated lipophilicity and limited aqueous solubility. No individual USP–NF or Ph. Eur. monograph currently assigns a compendial model number to this exact structure, so the pharmaceutical-grade specification is established under ICH Q7 and supported by route-specific impurity qualification, residual solvent validation, and elemental impurity risk assessment. The product is released through a certificate of analysis that includes identification, assay, related substances, water content, residue on ignition, residual solvents, and particle-size distribution appropriate to the intended route. For injectable use, additional endotoxin and particulate matter controls are applied; for solid oral use, particle-size distribution, bulk density, flow function, and compressibility are controlled.

What release specifications are required when no individual monograph exists?

The absence of a specific pharmacopoeial monograph does not remove the need for a complete release panel. The control strategy is built from ICH Q3A, ICH Q3C, ICH Q3D, and general chapters of the USP and Ph. Eur. Assay and related substances are determined by reversed-phase HPLC with UV detection, using a route-specific stationary phase and mobile phase that separates the 5-amino-3-(trifluoromethyl)pyridine-2-carbonitrile parent from chloro, methyl, and regioisomeric impurities. For an API with a maximum daily dose not exceeding 2 g/day, the reporting threshold is 0.05%, the identification threshold is 0.10%, and the qualification threshold is 0.15% under ICH Q3A; total impurities are usually controlled at not more than 0.5%. These thresholds are not automatically acceptance limits; each specified impurity is assigned a limit based on toxicological qualification, batch data, and the route of administration. Residual solvents are determined by headspace gas chromatography against ICH Q3C Option 1 limits; Class 1 solvents are excluded, and Class 2 solvents are controlled at or below their permitted daily exposure. Elemental impurities are assessed by ICP-MS according to the risk-based approach in ICH Q3D, with a focus on Class 1 and Class 2A elements. Water content is measured by Karl Fischer titration, with the limit set to protect hydrolytically sensitive functionality and to maintain solid-dosage flow properties. Loss on drying or thermogravimetric analysis may supplement water content when residual solvent and hydrate behavior must be distinguished. The exact numerical limits are not universal; they depend on the intended dose, route, and manufacturing process.

Identification includes infrared spectrophotometry and chromatographic retention time against a characterized reference standard. Pharmacopoeial general chapters used for the panel include USP <921> for water determination, USP <281> for residue on ignition, USP <232> and USP <233> for elemental impurities, and USP <429> for laser diffraction particle sizing. If the material is intended for injectable formulation, the panel is expanded to include bacterial endotoxin per USP <85>, sterility of the aseptic processing chain, and particulate matter per USP <788>. Because this exact compound lacks a monograph, any change in the synthetic route or the polymorphic form requires an update to the impurity profile and stability-indicating method.

The difference between pharmaceutical-grade 5-amino-3-(trifluoromethyl)pyridine-2-carbonitrile and technical-grade material is not molecular; the molecule is identical. The difference is control. Table 1 summarizes the practical release differentiation.

Compared with the 5-amino-3-chloropyridine-2-carbonitrile analog, the trifluoromethyl substituent has greater carbon–fluorine bond strength and higher lipophilicity; the trifluoromethyl group alters metabolic and dissolution behavior, but published equilibrium solubility and permeability data for this exact structure are limited. Compared with other regioisomers, the 2-carbonitrile/3-trifluoromethyl/5-amino arrangement changes crystal packing, hydrogen-bonding geometry, and potential degradation pathways. For this reason, incoming identity testing should use retention-time matching and should reject isomeric substitution. Differences from other products therefore arise from regioisomer identity, pharmaceutical-grade impurity control, and dosage-form-specific physical testing rather than from a separate pharmacopoeial monograph.

When the API is specified for aseptically processed injectable solutions

Injectable application expands the specification from chemical purity to microbial and particulate quality. The bacterial endotoxin limit is derived from the maximum dose per kilogram body weight per hour using the USP <85> formula K/M; for a non-intrathecal parenteral preparation, K is 5 EU/kg. If the maximum bolus dose per kg is not known, the manufacturer is required to define a conservative internal limit based on the intended dosing regimen. The API is not assumed to be pyrogen-free; a validated depyrogenation step is selected only after thermal and chemical stability studies. Dry-heat depyrogenation is effective above 250 °C for the container or glass vial, but the organic API itself is usually not exposed to dry heat; instead, endotoxin is controlled by using low-endotoxin raw materials, segregated handling, and sterile filtration of the formulated solution.

Sterile filtration involves a 0.22 µm membrane filter for sterilization of the formulated solution, but this is not sterilization of the API powder. If the API has limited aqueous solubility, a co-solvent system or pH adjustment may be required before filtration. High particle load or viscosity can reduce filter throughput; in production, a prefilter of 0.45 µm is used to protect the final sterilizing-grade membrane. Filter integrity is tested before and after use by bubble point, diffusive flow, or pressure hold per manufacturer technical bulletins. The formulated solution must meet particulate matter limits under USP <788>. For small-volume injections, the light obscuration method allows no more than 6000 particles per container at ≥10 µm and no more than 600 particles per container at ≥25 µm; the microscopic method allows 3000 and 300, respectively. For large-volume injections, the light obscuration limits are 25 particles per mL at ≥10 µm and 3 particles per mL at ≥25 µm. These particulate limits are pharmacopoeial requirements and are independent of the API's own particle-size distribution. They require low-shedding filter materials, closed transfer, and environmental control of filling.

Osmolality and pH of the ready-to-use or reconstituted solution must be measured; no published osmolality contribution data for this exact API are available in the public domain, so formulation development should use a freezing-point osmometer and pH meter calibrated with traceable buffers. An incompatibility may arise in the presence of strong nucleophiles because the nitrile group can hydrolyze under acidic or basic conditions; the degradation products should be monitored during forced degradation and stability. For injectable formulation, the selected salt form or free base, counterion, and solvent must be qualified for low endotoxin burden and low particulate contamination. USP <1> injections general chapter imposes container closure requirements, but the API specification does not replace finished-product release testing.

Particle-size control, polymorph consistency and solid-dosage processing

For tablet, capsule, and granule dosage forms, the particle-size distribution and powder flow properties control content uniformity, blend segregation, and dissolution rate. The as-received API may be processed through a conical mill, hammer mill, or jet mill to reduce the D90 or to narrow the distribution. Milling conditions are selected with respect to temperature rise because the trifluoromethyl and nitrile groups can impart thermal sensitivity; cooling jackets on a jet mill or low-speed conical milling under nitrogen may be used when the particle surface is reactive. Laser diffraction per USP <429> is used to report D10, D50, and D90. The specific target is formulation-dependent: a low-dose direct-compression tablet with a drug load below 5 mg may require a D90 below 75 µm to achieve blend uniformity, while a high-dose wet-granulated tablet may tolerate a larger D90 if the granulation step densifies and distributes the API. These figures are design targets, not universal limits; published batch data for this exact API are limited.

If direct compression is not feasible because of poor flow or compressibility, the API is incorporated into a high-shear granulator or fluid-bed granulator with a binder solution. Wet granulation introduces a drying step in which residual moisture, inlet air temperature, and exhaust dew point are monitored to avoid hydrolysis of the nitrile. Drying end points are confirmed by loss on drying or near-infrared moisture analysis. For capsule filling, the granule or powder is filled on a tamping-pin or dosator-type encapsulation machine; the fill weight and compaction settings are set to avoid plug formation and to maintain weight variation within USP <905> or Ph. Eur. 2.9.5. Tablet compression is performed on a rotary tablet press with force feeder speed and punch penetration adjusted to minimize picking, sticking, and capping. The final blend or granule is tested for bulk density, tapped density, compressibility index, and Hausner ratio to anticipate flow on the production line. The API's crystalline form is confirmed by X-ray powder diffraction before and after grinding; a polymorphic transformation during milling can cause dissolution changes and should be ruled out.

For oral granules, the API may be coated or layered onto a core, or blended with diluents, binders, disintegrants, and glidants. The dissolution method uses USP apparatus 2 or apparatus 4 depending on the release mechanism; because no public dissolution database exists for this specific API, the method is developed with the intended formulation and a discriminatory medium selection protocol. The API should not be assumed compatible with all excipients; the nitrile group may interact with primary amines under moisture and heat, so excipient compatibility studies using binary mixtures at accelerated storage conditions are required before formulation lock.

Forced degradation data bracket the stability-indicating limits

Acid hydrolysis, base hydrolysis, oxidative stress, thermal stress, and photostability are evaluated under ICH Q1A and ICH Q1B to demonstrate that the analytical method is stability-indicating. The nitrile and trifluoromethyl-adjacent positions are the main sites of potential hydrolysis and oxidative degradation; the HPLC method is adjusted so that the parent peak is separated from the resulting degradation products at a resolution of at least 1.5. Degradation products above the ICH Q3A identification threshold are characterized by LC-MS or preparative isolation. Long-term storage conditions for climatic zones I and II are 25 °C at 60% RH and accelerated conditions are 40 °C at 75% RH, per ICH Q1A. If the development candidate is intended for zone III or IV, storage conditions of 30 °C/65% RH or 30 °C/75% RH are applied. The API packaging is selected based on moisture vapor transmission rate to avoid water uptake that accelerates hydrolysis. Published stability data for this exact compound are limited; therefore, the manufacturer must generate product-specific data before setting a retest period.